Cathepsin B-responsive and gadolinium-labeled branched glycopolymer-PTX conjugate-derived nanotheranostics for cancer treatment.
- Author:
Hao CAI
1
;
Yufan XIANG
1
;
Yujun ZENG
1
;
Zhiqian LI
1
;
Xiuli ZHENG
1
;
Qiang LUO
1
;
Hongyan ZHU
2
;
Qiyong GONG
1
;
Zhongwei GU
1
;
Yanhui LIU
1
;
Hu ZHANG
3
;
Kui LUO
1
Author Information
- Publication Type:Journal Article
- Keywords: Biodegradability; Branched glycopolymers; Drug delivery; Nanomedicine; Stimuli-responsive; Theranostics
- From: Acta Pharmaceutica Sinica B 2021;11(2):544-559
- CountryChina
- Language:English
- Abstract: Multi-modal therapeutics are emerging for simultaneous diagnosis and treatment of cancer. Polymeric carriers are often employed for loading multiple drugs due to their versatility and controlled release of these drugs in response to a tumor specific microenvironment. A theranostic nanomedicine was designed and prepared by complexing a small gadolinium chelate, conjugating a chemotherapeutic drug PTX through a cathepsin B-responsive linker and covalently bonding a fluorescent probe pheophorbide a (Ppa) with a branched glycopolymer. The branched prodrug-based nanosystem was degradable in the tumor microenvironment with overexpressed cathepsin B, and PTX was simultaneously released to exert its therapeutic effect. The theranostic nanomedicine, branched glycopolymer-PTX-DOTA-Gd, had an extended circulation time, enhanced accumulation in tumors, and excellent biocompatibility with significantly reduced gadolinium ion (Gd
